YOU ARE ABOUT TO EXIT A GLOBAL HEMANEXT ONE PRODUCT WEBSITE FOR THE US HEMANEXT CORPORATE WEBSITE
Please be aware that the website you have requested is intended for the residents of the United States. The Hemanext One® System has not been cleared, approved, or otherwise authorized by the US Food & Drug Administration for commercial distribution in the United States.
WITH DO YOU WISH TO CONTINUE AND EXIT THIS WEBSITE?
Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food and Drug Administration (FDA) LEXINGTON, Mass., September 21, 2023, –Hemanext Inc., a leading innovator in blood processing, storage, and...
LEXINGTON, Mass., September 18, 2023, – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, marks a significant turning point in its history as the company announces the retirement of its founder, Martin Cannon. Simultaneously,...
LEXINGTON, Mass., July 5, 2023, –Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, today announced its membership in the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), the region’s premier trade...
Partnership to include research and development at Vitalant Innovation Center LEXINGTON, Mass., June 7, 2023, – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, today announced a new partnership with Vitalant, one of the...
Groundbreaking technology to be deployed to transfuse thalassemia patients in Italy and acute bleeding burn patients in Norway LEXINGTON, Mass., May 25, 2023, –Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, today announced...
Raises $18 Million in New Equity Financing Appoints Healthcare Luminary Dr. Ismail Kola to Board of Directors, Adding Clinical Development Expertise Progresses European Commercial Launch with Rollout to Key Distributors and Leading Hospitals and Blood Centers ...
